An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
2008

Predicting Response to Lenalidomide in Myelodysplastic Syndrome

Sample size: 42 publication Evidence: high

Author Information

Author(s): Ebert Benjamin L, Galili Naomi, Tamayo Pablo, Bosco Jocelyn, Mak Raymond, Pretz Jennifer, Tanguturi Shyam, Ladd-Acosta Christine, Stone Richard, Golub Todd R, Raza Azra

Primary Institution: Broad Institute of Harvard and Massachusetts Institute of Technology

Hypothesis

Can gene expression profiling predict lenalidomide response in myelodysplastic syndrome patients without 5q deletions?

Conclusion

The study found that a specific gene expression signature can predict which myelodysplastic syndrome patients are likely to respond to lenalidomide treatment.

Supporting Evidence

  • Gene expression profiling identified a set of genes that predict lenalidomide response.
  • The response signature was validated in an independent set of samples.
  • Patients with decreased expression of the erythroid differentiation signature were more likely to respond to lenalidomide.
  • Lenalidomide treatment promoted erythroid differentiation in vitro.

Takeaway

Researchers figured out a way to tell which patients with a blood disorder will benefit from a medicine called lenalidomide by looking at their genes.

Methodology

Gene expression profiling was used to identify a molecular signature in bone marrow samples from patients with myelodysplastic syndrome.

Limitations

The predictive test needs further validation in larger patient populations before clinical use.

Participant Demographics

Patients with low- or intermediate-1-risk myelodysplastic syndrome, including those with and without 5q deletions.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pmed.0050035

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication